Core Viewpoint - The company has experienced a decline in revenue and net profit in the first half of 2025, but has shown improvements in operational efficiency and service volume, indicating potential for recovery in the second half of the year [1][2][5]. Company Performance - In the first half of 2025, the company achieved operating revenue of 203,430.77 million yuan, a year-on-year decrease of 15.95% [2]. - The net profit attributable to shareholders was -16,496.18 million yuan, a year-on-year reduction in losses of 4.98% [2]. - The overall emergency and outpatient service volume reached 1.3191 million visits, an increase of 5.42% year-on-year [2]. - The net cash flow from operating activities was 59,254.20 million yuan, a year-on-year increase of 12.75% [2]. Hospital Operations - Xi'an Gaoxin Hospital reported emergency and outpatient visits of 578,700, a year-on-year increase of 3.04%, but inpatient visits decreased by 6.48% [3]. - Xi'an International Medical Center Hospital had emergency and outpatient visits of 740,500, a year-on-year increase of 7.37%, while inpatient visits decreased by 2.80% [3]. - Revenue for Xi'an International Medical Center Hospital was 138,327.49 million yuan, a year-on-year decrease of 15.37%, with a net profit of -11,320.98 million yuan, a decline of 44.63% [3]. Strategic Initiatives - The company is focusing on cost control through bed integration and departmental optimization, increasing the use of centralized procurement drugs and those meeting DRG payment standards [4]. - The company is developing specialty services such as health management, aesthetic medicine, physical examinations, elderly care, and international cooperation [4]. - Research in stem cells includes over 500 testing projects, with significant progress in clinical trials for mesenchymal stem cell treatments [4]. Future Outlook - For the second half of 2025, the company aims to maintain steady operations, enhance cost control, and improve efficiency while focusing on medical quality and patient service [6]. - The company plans to implement differentiated strategies to enhance added value and adapt to industry changes for orderly service expansion and improved profitability [6].

Core Viewpoint - Xi'an International Medical Investment Co., Ltd. has made significant progress in its operational development in the first half of 2025, focusing on enhancing service quality, optimizing operational efficiency, and expanding its business layout [2][3]. Group 1: Operational Achievements - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million visits, a year-on-year increase of 5.42%, while inpatient service volume decreased by 4.01% to 96,300 visits [3]. - The company reported a revenue of 2,034.31 million yuan, a year-on-year decrease of 15.95%, and a net profit attributable to shareholders of -164.96 million yuan, a reduction in losses by 4.98% [3]. - The net operating cash flow was 592.54 million yuan, reflecting a year-on-year increase of 12.75%, indicating stable medical business collections and good capital turnover [3]. Group 2: Business Development and Innovations - The company established new specialized clinical departments and completed 636 clinical application filings for restricted technologies, along with obtaining 24 national authorized patents [2]. - The company has expanded its service offerings by establishing specialized treatment services such as geriatrics and proton therapy to meet market demand [2]. - The integration of artificial intelligence and the expansion of internet hospital services have improved patient service processes and enhanced operational efficiency [2]. Group 3: Financial Performance of Subsidiaries - Xi'an High-tech Hospital reported an outpatient service volume of 578,700 visits, a year-on-year increase of 3.04%, while inpatient service volume decreased by 6.48% [4]. - Xi'an International Medical Center Hospital had an outpatient service volume of 740,400 visits, a year-on-year increase of 7.37%, but a net profit of -113.21 million yuan, a decrease of 44.63% [4]. Group 4: Future Strategies - The company plans to enhance cost control through bed integration and departmental optimization, as well as increase the use of drugs that meet DRG payment standards [5]. - The focus will be on health management, aesthetic medicine, physical examinations, elderly care, and international cooperation to implement differentiated business strategies [5]. - The company aims to strengthen cost control and efficiency while enhancing medical quality and service experience to build competitive advantages and achieve steady growth [6].

证券代码：000516 证券简称：国际医学 编号：2025-05 随着公司旗下医疗机构对 DRG 支付方式改革的适应性正逐步 增强，住院患者服务量稳定，门诊业务持续扩大。 西安国际医学投资股份有限公司投资者关系活动记录表 | | 特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 业绩说明会 | | 投资者关系活动 | □新闻发布会 路演活动 | | 类别 | 现场参观 | | | 其他_____ | | 参与单位名称及 | 开源证券组织走进国际医学活动投资者 29 位 | | 人员姓名 | | | 时间 | 2025 年 8 月 26 日 14:30-17:00 | | 地点 | 西安国际医学中心医院 | | 上市公司接待人 | 副总裁兼董事会秘书丁震 | | 员姓名 | | | | 公司联合开源证券组织"投资者走进国际医学活动"。投资 | | | 者重点参观西安国际医学中心医院康复治疗中心、康复水疗中 | | | 心、VIP 健康管理中心、产后保健中心等重点特色科室，并介绍 | | | 公司经营发展的简要情况，主要内容如下： | | | 1、2025 年上半年公司经营 ...

Group 1 - The Beijing Municipal Government has announced the 2024 Science and Technology Awards, recognizing significant contributions in scientific research and technology development [1] - The "Outstanding Contribution Zhongguancun Award" was awarded to Deng Hongkui and Dong Jin for their major breakthroughs in scientific research and technology [1] - Deng Hongkui is recognized for his pioneering work in stem cell research, particularly in developing methods to regulate cell fate and creating new technologies for pluripotent stem cell preparation [1] - Dong Jin is acknowledged for his research in blockchain technology and chip development, leading the creation of the "Chang'an Chain," a fully controllable blockchain technology [1] Group 2 - The awards also included the "Beijing Outstanding Youth Zhongguancun Award" given to 26 young scientists, and the "Beijing International Cooperation Zhongguancun Award" awarded to 10 foreign scientists [2] - A total of 15 projects received the first prize in the Beijing Natural Science Award, including research on glucose transport proteins [2] - The Beijing Technology Invention Award recognized 6 projects with first prizes, including key substrate technology for gallium nitride-based light-emitting devices [2] - The Beijing Science and Technology Progress Award awarded first prizes to 29 projects, including the establishment and promotion of key technologies for artificial heart clinical applications [2]

Core Insights - Researchers have successfully induced stem cells to develop into a fluid-filled amniotic sac model, measuring approximately 2 centimeters in diameter, which corresponds to the size of an amniotic sac surrounding a 4-week embryo, providing a new avenue for studying early pregnancy [1][2] Group 1 - The amniotic sac is a transparent membrane that forms a fluid-filled pouch to protect the developing embryo, but obtaining and studying this tissue in early pregnancy has been challenging [1] - The study published in "Cell" showcases the most advanced amniotic sac model to date, highlighting its large scale and reproducibility as significant advantages [1] - The model was created by stimulating embryonic stem cells with a signaling molecule on the first and second days, followed by placing the cells in a culture medium, leading to the formation of miniature fluid-filled sacs over three months [1] Group 2 - The researchers observed that these cells mimicked the characteristics of a 4-week human amniotic sac, forming a double-layered membrane structure filled with fluid, similar to the yolk sac structure that provides nutrients to the embryo [2] - The volume of the amniotic sac is sufficient for the research team to extract and analyze the fluid, which is rich in proteins and metabolites crucial for fetal health, resembling substances found in human amniotic fluid during later stages of pregnancy [2] - There is uncertainty regarding the model's accuracy in simulating later-stage amniotic development, which is essential for studying severe complications arising from amniotic damage [2]